All News

Despite Limitations, Oral Mobocertinib Offers Ongoing Benefits for Lung Cancer Subset, Says Expert
November 30, 2022

An expert from NYU Langone in New York City recently discussed the strengths and limitations of the oral tyrosine kinase inhibitor mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion+ metastatic non-small cell lung cancer.

Real-World Data Supports Use of Hypomethylating Drugs in Elderly Patients With Acute Myeloid Leukemia
November 30, 2022

The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.

FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer Subset
November 30, 2022

The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.

Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMD
November 30, 2022

Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.

Addition of Rezvilutamide to ADT Improves OS and rPFS Vs Bicalutamide/ADT in Hormone-Sensitive Prostate Cancer
November 30, 2022

Rezvilutamide with androgen-deprivation therapy yielded improved overall survival and radiographic progression-free survival compared with bicalutamide and androgen-deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer.

FDA Grants Investigational CAR-T Cell Therapy CB-010 2 Designations for B-Cell Non-Hodgkin Lymphoma
November 29, 2022

The allogeneic anti-CD19 CAR-T cell therapy CB-010 has received 2 designations from the FDA, including a fast-track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.

Atezolizumab No Longer Available in US for a Certain Type of Bladder Cancer
November 29, 2022

Atezolizumab is no longer available to treat patients with advanced or metastatic bladder cancer following the manufacturer’s decision to withdraw its U.S. indication after consulting with the FDA.

Real-World Findings Suggest mFOLFOX6 Treatment Resulted in Less Oxaliplatin Vs Historic Control in Colon Cancer
November 29, 2022

Real-world patients with stage III colon cancer who were treated in the community practice setting with modified FOLFOX6 received less oxaliplatin vs historic controls from the phase 3 MOSAIC trial.

Race, Ethnicity ‘Notably Underreported’ in Publicly Accessible Databases of Gynecologic Cancer Trials
November 29, 2022

Findings from a recent 30-year analysis of more than 1,000 gynecologic cancer trials strongly suggest that reporting race and ethnicity must be a required part of clinical research to improve diversity, according to a group of researchers.

Data Support Whole Brain Irradiation Reduction in Pediatric Cancer Survivors
November 28, 2022

Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.